Keyword: Bristol-Myers Squibb
BMS is combining Opdivo and cabiralizumab, an anti-CSF-1 antibody, with Apexigen’s lead CD40 activator in an early-phase solid tumor study.
Idera Pharmaceuticals' TLR antagonist, IMO-8400, failed to improve skin symptoms in adults with dermatomyositis.
Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.
Nektar’s much-anticipated data from a study pairing its NKTR-214 with Bristol-Myers Squibb’s Opdivo have resulted in a lot of head-scratching.
Using an old Roche drug, Madrigal Pharmaceuticals has seen its stock soar 130% on its latest fatty liver disease trials data.
Lilly’s oncology chief is retiring; a GSK vet is launching a Chinese public health startup; and Gilead’s R&D chief is going back to his roots.
Curis is bringing on board member Robert Martell, formerly CMO at Tesaro, as a full-time employee in the newly created role to head its R&D.
Astellas will discontinue work at its R&D subsidiary by March 2019, offering early retirements to 600 staff, as exclusivity losses loom next year.
Galecto Biotech hired Richard Marshall, head of fibrosis discovery at GlaxoSmithKline, to be CMO as it moves into late-phase trials of its IPF drug.
Frances Rena Bahjat, BMS’ former director of in vivo studies, joined Apexigen in a newly created role.